All News
ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Read Article
Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%).
@RheumNow #ACR24 #GCTox
Akhil Sood MD AkhilSoodMD ( View Tweet)
Biosimilar switching in practice
Hyrich: UK experience
Switching to biosimilar has no immediate benefit to patients but saves NHS money
Allows for gain share that can be re-invested in pt care
Transparency in switching in explaining to pts and offering resource
@RheumNow #ACR24
Eric Dein ericdeinmd ( View Tweet)
Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset
@RheumNow #ACR24 https://t.co/TLDSiBZZPs
Akhil Sood MD AkhilSoodMD ( View Tweet)
Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term.
Key findings:
- AxSpA: 3.7% incidence (1.3/100 PY) with BKZ.
- PsA: Only 0.2% incidence (0.1/100 PY).
- All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much
@RheumNow #ACR24 https://t.co/jn52ujtspo
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Hyrich:
ETN originator vs biosimilar initiation
- DAS28 - no signif change at B/L, 6mo, 12 mo.
Switch?
Matched pts in ETN switch v cont originator - good b/l control on Rx
-DAS28 maintained w switch
10% did go back to originator, felt less good tho similar DAS
#ACR24 @RheumNow https://t.co/RHRit5CtUu
Links:
Eric Dein ericdeinmd ( View Tweet)
Food for thought 🤔
Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were higher among individuals with incident SpA compared to controls
@RheumNow #ACR24 https://t.co/qUXcxSfTxE
Akhil Sood MD AkhilSoodMD ( View Tweet)
Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use
But is T2T met?
LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA
#ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq
Jiha Lee JihaRheum ( View Tweet)
Early observational data suggesting JAK inhibitors can play a role in TAK tx
We have seen this with UPA in GCA this conference… time for SELECT-TAK !
@RheumNow #ACR24 https://t.co/B2Wa8sOFTp
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 1912: Time to close the gaps in #PsA care
RISE Registry reveals:
- higher disease activity in the South
- more oral steroids + csDMARDs, fewer bDMARDs, and more comorbidities in the Midwest
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic
@andreafava why isn't this just more-testing & more-sensitive testing shifting the phenotype of who we diagnose?
#ACR24 @RheumNow Abstr#2413 https://t.co/o2e9TFMsUp
Links:
Mike Putman EBRheum ( View Tweet)
Lots of data on TYKs including much supporting efficacy in interferon inhibition
Can we really call interferon signalling a "central" pathway in SLE?
Inhibiting it has been modestly successful, at best, and mostly for skin dx
#ACR24 @RheumNow Abstr#2434 https://t.co/Q94FQz3gzO
Mike Putman EBRheum ( View Tweet)
#2222
📊 New data on #RA-ILD:
🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incidence at 5 years (IR 14.9/1000 PY).
🔴ILD often precedes or coincides with RA onset.
🔴NSIP > UIP
🔴airway involvement less common than expected.
#acr24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adults with psoriatic arthritis (PsA).
Key findings:
- 42,821 PsA patients analyzed; only 1.1% on combination therapy.
- Increased risk of serious infections:… https://t.co/Jghmz9lkLd https://t.co/YqwJlTKcEi
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RA patients affected by frailty at a younger age
in @VARA frailty associated with lower BMD
But frailty is modifiable!
#GeriRheum
#ACR24 @RheumNow ABST#2140 https://t.co/BoTGoESB43
Jiha Lee JihaRheum ( View Tweet)
Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr A Askanase #ACR24 LN Guidelines @RheumNow https://t.co/4BBuAWi2da
Links:
TheDaoIndex KDAO2011 ( View Tweet)
Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24
MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/iH9IZmHhSz https://t.co/am5LoBCdpe
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
A#2528
Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus
Yoda1 - Piezo1 agonist shown to help fx healing in mice
Piezo1 decrease in GIOP
Basic sci research shows activation of pathway promotes mechanical stress response, decr GIOP
#ACR24 @RheumNow
Eric Dein ericdeinmd ( View Tweet)